



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Wednesday June 18, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date |
|--------------------|----------------------------------|--|------------|
| TLXAO | SHARE APPRECIATION RIGHTS | 166,483 | 13/06/2025 |
| TLXAU | DEFERRED SHARE RIGHTS EX-US 2024 | 2,595 | 13/06/2025 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

18/6/2025



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

13/6/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|-----------------------|---------------------------|-----------------------|
| Christian Behrenbruch | Christian Behrenbruch | 166,483 |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's 2024 Remuneration Report, within the 2024 Annual Report and to Telix's 2025 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at <https://ir.telixpharma.com/reports>

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights (notional exercise price \$28.67) granted to Managing Director and Group Chief Executive Officer, Christian Behrenbruch, as part of his Target Total Remuneration Package for FY25 following shareholder approval at the Company's AGM held on 21 May 2025. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan Rules, with a measurement period of 2025-2027. For further details, refer to the Remuneration Report in Telix's 2024 Annual Report accessible at <https://ir.telixpharma.com/reports>

Issue details

Number of +securities

166,483

ASX +security code and description

TLXAU : DEFERRED SHARE RIGHTS EX-US 2024

Date the +securities the subject of this notification were issued

13/6/2025

Will these +securities rank equally in all respects from their issue date with the existing issued



+securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|-----------------------|---------------------------|-----------------------|
| Christian Behrenbruch | Christian Behrenbruch | 2,595 |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's 2024 Remuneration Report, within the 2024 Annual Report and to Telix's 2025 Annual General Meeting Notice of Meeting for Deferred Share Rights valuation methodology, accessible at <https://ir.telixpharma.com/reports>

Any other information the entity wishes to provide about the +securities the subject of this notification

Deferred Share Rights (nil exercise price) granted to Managing Director and Group Chief Executive Officer, Christian Behrenbruch, as part of his Target Total Remuneration Package for FY24 following shareholder approval at the Company's AGM held on 21 May 2025. Vesting is subject to service condition being met and the terms of Telix's Equity Incentive Plan Rules. For further details, refer to the Remuneration Report in Telix's 2024 Annual Report accessible at <https://ir.telixpharma.com/reports>

Issue details

Number of +securities

2,595



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| TLX : ORDINARY FULLY PAID | 338,248,789 |

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL | 80,000 |
| TLXAR : PERFORMANCE RIGHTS | 9,965,235 |
| TLXAP : SHARE RIGHTS | 1,440,000 |
| TLXAO : SHARE APPRECIATION RIGHTS | 15,810,389 |
| TLXAT : CONVERTIBLE NOTES | 3,250 |
| TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37 | 304,992 |
| TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL | 100,000 |
| TLXAU : DEFERRED SHARE RIGHTS EX-US 2024 | 10,561 |
| TLXAV : DEFERRED SHARE RIGHTS US 2024 | 10,342 |
| TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025 | 2,881,250 |
| TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38 | 289,225 |
| TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS | 440,000 |



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

14